Restoring a Natural Antimicrobial Peptide Made Aggressive Breast Cancer Respond to Chemotherapy | Research

The takeaway

Injecting human beta defensin-1 (hBD-1) peptide into triple-negative breast cancer tumors in mice activated cell death pathways and significantly reduced tumor volume when combined with doxorubicin chemotherapy.

First in vivo hBD-1 injection
The first demonstration that injecting human beta defensin-1 peptide can restore tumor suppressor function and sensitize triple-negative breast cancer to chemotherapy in a living model

What the researchers found

Human beta defensin-1 (hBD-1) was shown to target the tumor-specific biomarker thioredoxin (Trx) and activate two cell death pathways — CD95 (Fas) and ASK1 (apoptosis stimulating kinase 1) — that are dysregulated in TNBC. Injection of hBD-1 into TNBC mouse models restored the peptide to basal levels and sensitized previously resistant cancer cells to doxorubicin chemotherapy.

The combination of hBD-1 restoration plus doxorubicin produced significant tumor volume reduction in vivo compared to chemotherapy alone. This represents the first demonstration that injecting hBD-1 can restore its tumor-suppressor function and sensitize TNBC to chemotherapy in a living animal model.

Why it matters

TNBC accounts for about 15% of breast cancers and disproportionately affects younger women and Black women. With no targeted therapies available (it lacks the ER, PR, and HER2 receptors that other breast cancers have), patients rely on chemotherapy that often fails due to resistance. If hBD-1 can sensitize these tumors to work at lower chemotherapy doses, it could both improve outcomes and reduce the severe side effects that make TNBC treatment so debilitating.

How the study worked

Researchers used TNBC cell lines and mouse tumor models. They first established that hBD-1 expression is lost at high frequency in malignant cancers while maintained in benign tissue. They then injected hBD-1 peptide into TNBC tumors in mice and administered doxorubicin chemotherapy. The study measured activation of CD95 and ASK1 apoptosis pathways, thioredoxin targeting, and tumor volume changes. The approach was termed AAAPT (A priori Activation of Apoptosis Pathways of Tumor).

What this study cannot tell us

This is a preprint (bioRxiv) that has not undergone peer review, which means the findings have not been independently validated by other scientists. The study used mouse models, and the results may not translate directly to human patients. Specific statistical details, tumor volume measurements, and group sizes are not clearly reported in the abstract. The delivery method (direct tumor injection) is not practical for metastatic disease, and systemic delivery approaches would need to be developed for clinical use.

How to read the evidence

This is a preprint preclinical study using mouse tumor models. While the concept is novel and the in vivo results are promising, the lack of peer review, limited statistical detail, and early-stage nature of the research place it at a preliminary evidence level. The findings require independent validation and eventual clinical testing.

When this study was published

Published as a 2023 preprint on bioRxiv. As a non-peer-reviewed preprint, these findings should be interpreted with additional caution until formally published in a peer-reviewed journal.

The bigger picture

Defensins are among the body's most ancient antimicrobial peptides, and their roles in cancer biology are increasingly recognized. This study reframes hBD-1 not just as an immune peptide but as a lost tumor suppressor that, when restored, can overcome chemotherapy resistance. The concept of using natural peptides to 'sensitize' resistant cancers rather than developing entirely new drugs is an elegant approach that could be broadly applied to other cancers where defensin expression is lost.

Questions still open

Can hBD-1 be delivered systemically rather than by direct injection to treat metastatic TNBC?
Does hBD-1 restoration sensitize other chemotherapy-resistant cancer types beyond TNBC?
What is the optimal dose and schedule for combining hBD-1 with reduced-dose chemotherapy to maximize efficacy while minimizing side effects?

Common questions

What are defensins and why would cancer cells lose them?

Defensins are small antimicrobial peptides that are part of the body's innate immune system. Human beta defensin-1 (hBD-1) normally helps fight infections but also acts as a tumor suppressor by activating cell death pathways. Cancer cells frequently silence hBD-1 expression because it would otherwise trigger their destruction. By losing this peptide, tumor cells escape immune surveillance and become resistant to treatments that rely on activating cell death — essentially removing their own 'self-destruct button.'

Why is triple-negative breast cancer so hard to treat?

Most breast cancers have receptors (ER, PR, or HER2) that can be targeted by specific drugs like tamoxifen or Herceptin. Triple-negative breast cancer lacks all three, leaving chemotherapy as the only systemic treatment option. Many TNBC tumors also develop resistance to chemotherapy by shutting down the cell death pathways that these drugs rely on. This study's approach of using hBD-1 to reactivate those pathways could make existing chemotherapy effective again, even at lower doses.

Read the original research

Restoration of the Lost Human Beta Defensin (hBD-1) in Cancer as a Strategy to Improve the Efficacy of Chemotherapy.

bioRxiv : the preprint server for biology

View on PubMed ↗Publisher’s paper ↗

Citation

Pandurangi, Raghu S; Sekar, Thillai V; Paulmurugan, Ramasamy. (2023). Restoration of the Lost Human Beta Defensin (hBD-1) in Cancer as a Strategy to Improve the Efficacy of Chemotherapy.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2023.04.03.535411